Story
CVS Health Stock May See 5.8% Swing on August Earnings, Options Data Shows

Summary
Options market data indicates a potential 5.8% price swing for CVS Health Corp. shares following its August 5 earnings release. Historically, the stock's actual post-earnings move has exceeded options-based expectations in five of the last eight quarters.
Options market data indicates a potential 5.8% price swing for CVS Health Corp. (NYSE:CVS) shares when the company reports earnings on August 5. The healthcare giant is scheduled to release its financial results before the market opens, and the implied move provides a key gauge of trader expectations for post-announcement volatility.
Market Expectations vs. Historical Reality
The 5.8% figure, compiled by Bloomberg, represents the stock's implied volatility derived from options contracts. It reflects the market's consensus on the magnitude of the price change, either up or down, following the release.
However, an analysis of the past eight quarters shows that CVS has a history of making larger-than-expected moves. The stock's actual price change has surpassed the implied volatility in five of those eight earnings announcements. This suggests that traders may be underestimating the potential for a significant reaction.
A Pattern of Volatility
AdA review of recent earnings reports highlights this trend:
- May 2026: Shares moved 7.3%, exceeding the 5.4% implied move.
- February 2025: Shares surged 12.2%, well above the 7.1% expected move.
- August 2024: The stock declined 10.6%, a much larger drop than the 6% priced in by options.
Conversely, the stock has also underperformed expectations at times. Following its February 2026 report, CVS shares moved just 0.4% against an implied swing of 5.1%. This historical data provides important context for investors, indicating that while options provide a baseline, the company's results can serve as a catalyst for a more substantial market reaction.
Read next
More on Stocks
ClearPoint Neuro Stock Plummets 24% on uniQure's Huntington's Trial Setback
Shares of ClearPoint Neuro fell sharply after its partner, uniQure, announced that its experimental gene therapy for Huntington's disease failed to meet its primary goal in a clinical trial, raising concerns about future revenue for ClearPoint's delivery technology.

Webull to Launch No-Code AI Tool for Trade Preparation via Claude, Perplexity
The online brokerage is expanding its cloud-based AI integration, allowing eligible U.S. users to research markets and prepare trades using natural language on platforms like Claude and Perplexity, without any software installation.

Iovance Biotherapeutics Raises Revenue Forecast on Strong Amtagvi Demand, Shares Surge
The biotech company boosted its full-year 2026 revenue guidance by approximately 15% at the midpoint, citing accelerating demand for its cancer therapies Amtagvi and Proleukin.

J.P. Morgan Upgrades Bureau Veritas to Overweight on Growth and M&A Outlook
J.P. Morgan raised its rating on the inspection and certification firm to “Overweight,” citing an expected recovery in organic growth driven by data centers and an increased capacity for acquisitions.